» Articles » PMID: 30742956

Use of Non-carbapenem Antibiotics to Treat Severe Extended-spectrum β-lactamase-producing Enterobacteriaceae Infections in Intensive Care Unit Patients

Abstract

Objectives: The aim of this study was to evaluate the use of non-carbapenem antibiotics to treat severe extended-spectrum β-lactamase-producing Enterobacteriaceae (ESBL-E) infections in intensive care unit (ICU) patients.

Methods: This retrospective observational study conducted in two ICUs compared the outcomes of patients with ESBL-E infections administered a carbapenem or a non-carbapenem antibiotic as their definitive treatment. The primary outcome was treatment failure within 30 days, a composite endpoint of ESBL-E infection recurrence and 30-day mortality. Secondary outcomes included 30-day and in-hospital mortality rates, ESBL-E infection recurrence and infection(s) due to other pathogen(s).

Results: Among 107 patients included in the study, 67 received a carbapenem and 40 received a non-carbapenem antibiotic as their definitive treatment. Clinical characteristics of the two groups were similar. Comparing patients given a non-carbapenem antibiotic with those administered a carbapenem, they had similar 30-day treatment failure (43% vs. 61%, respectively; P = 0.06) and ESBL-E infection recurrence rates (25% vs. 22%; P = 0.8), but the former had lower 30-day mortality (23% vs. 45%; P = 0.02) and in-hospital mortality rates (23% vs. 49%; P = 0.005). Secondary infection rates caused by other pathogen(s), including Clostridium difficile, were comparable. Outcomes were comparable regardless of whether or not patients received an empirical carbapenem.

Conclusion: For ICU patients with severe ESBL-E infections, treatment with a non-carbapenem antibiotic was not associated with poorer outcomes compared with a carbapenem antibiotic.

Citing Articles

Optimization of antibiotic use in the intensive care unit: how we do it.

Moniz P, Fustiga J, Herculano M, Povoa P Crit Care Sci. 2024; 36:e20240017en.

PMID: 39442132 PMC: 11554294. DOI: 10.62675/2965-2774.20240017-en.


Carbapenems β-lactam and β-lactamase inhibitors for treatment of nosocomial pneumonia: A systematic review and meta-analysis.

Cang H, Quan X, Chu X, Liang Y, Yang X, Li J Heliyon. 2023; 9(10):e20108.

PMID: 37767465 PMC: 10520732. DOI: 10.1016/j.heliyon.2023.e20108.


Antibiotic stewardship in the ICU: time to shift into overdrive.

Mokrani D, Chommeloux J, De Chambrun M, Hekimian G, Luyt C Ann Intensive Care. 2023; 13(1):39.

PMID: 37148398 PMC: 10163585. DOI: 10.1186/s13613-023-01134-9.


Efficacy of carbapenem vs non carbapenem β-lactam therapy as empiric antimicrobial therapy in patients with extended-spectrum β-lactamase-producing Enterobacterales urinary septic shock: a propensity-weighted multicenter cohort study.

Cariou E, Griffier R, Orieux A, Silva S, Faguer S, Seguin T Ann Intensive Care. 2023; 13(1):22.

PMID: 36959425 PMC: 10036246. DOI: 10.1186/s13613-023-01106-z.


Pharmacokinetics, efficacy and tolerance of cefoxitin in the treatment of cefoxitin-susceptible extended-spectrum beta-lactamase producing Enterobacterales infections in critically ill patients: a retrospective single-center study.

Chabert P, Provoost J, Cohen S, Dupieux-Chabert C, Bitker L, Ferry T Ann Intensive Care. 2022; 12(1):90.

PMID: 36175707 PMC: 9522958. DOI: 10.1186/s13613-022-01059-9.